BAYN.DE Bayer AG (XETRA) pre-market: earnings due 04 Mar 2026, guidance key
We open pre-market on 27 Feb 2026 with BAYN.DE stock trading at €41.85, down 1.73% from the previous close on volume of 2,248,276 shares. Bayer AG (XETRA) reports quarterly results on 04 Mar 2026, and investors will watch guidance, crop-science margins, and pharma launches. Key pre-earnings signals: 50-day average €41.42, 200-day average €31.18, and market cap about €41.11B. This earnings spotlight links recent headlines from Reuters and a U.S. ticker update at MarketWatch.
Earnings preview: BAYN.DE stock and what to expect
Bayer AG reports on 04 Mar 2026 and BAYN.DE stock will react to revenue trends, margin guidance, and legal updates. Management commentary on Crop Science pricing and Pharmaceuticals growth will likely move the shares. Analysts will also watch free cash flow and any update to the dividend policy ahead of the call.
BAYN.DE stock: recent performance and valuation metrics
At €41.85, the share price sits near the 50-day average of €41.42 and well above the 200-day average of €31.18, reflecting a recovery from the 52-week low of €18.38. Trailing EPS is -0.20 with a negative PE of -209.22, while price-to-sales is 0.90 and price-to-book is 1.39. These ratios show a business with solid sales but earnings pressure from restructuring and legacy costs.
BAYN.DE stock: balance sheet, cash flow and dividends
Bayer carries significant liabilities with debt-to-equity near 1.34 and enterprise value about €74.85B. Operating cash flow per share is €6.85 and free cash flow per share is €4.01, supporting a free cash flow yield of 9.58%. The current dividend per share is €0.11, implying a yield of about 0.26%, and any dividend clarity at earnings will matter for income investors.
BAYN.DE stock: technicals and trading setup
Technical indicators show the RSI at 41.25, a neutral-to-slightly-oversold reading, and ADX 33.88 signaling a strong trend. Bollinger Bands middle at €45.04 and lower at €41.67 put today’s price near the lower band, increasing the chance of short-term volatility around the report. Average volume is 3,887,175; today’s volume of 2,248,276 is light, so moves could accelerate on news.
Meyka AI grade and BAYN.DE stock forecast
Meyka AI rates BAYN.DE with a score out of 100: 68.91 (Grade B, HOLD). This grade factors in S&P 500 and sector comparison, financial growth, key metrics, forecasts, and analyst consensus. Meyka AI’s forecast model projects a 12-month target of €49.38, implying +17.98% upside vs the current €41.85; forecasts are model-based projections and not guarantees.
BAYN.DE stock: risks, catalysts and sector context
Key catalysts are Pharma pipeline readouts, Crop Science pricing, and any legal settlement detail. Main risks include leverage (net debt to EBITDA elevated) and margin compression in Crop Science. In the German Healthcare sector, peers show stronger ROE, so Bayer’s relative rebound depends on execution and clearer guidance at earnings.
Final Thoughts
BAYN.DE stock opens pre-market on 27 Feb 2026 at €41.85 with earnings due on 04 Mar 2026. Investors should focus on guidance for Crop Science and Pharmaceuticals, free cash flow stability, and any update on litigation provisions. Technicals point to near-term volatility; RSI 41.25 and Bollinger lower band €41.67 show the stock is close to short-term support. Meyka AI’s forecast model projects a 12-month target of €49.38, implying +17.98% upside from €41.85, but forecasts are model-based projections and not guarantees. For traders, a conservative base price target is €49.00, a cautious downside support near €38.00, and a bull case to €60.00 if guidance surprises positively. We also link the company page for quick reference at BAYN.DE at Meyka and cite recent coverage at Reuters. Use earnings day to re-evaluate risk exposure and position sizing; we recommend watching guidance and cash flow metrics closely before adjusting allocations.
FAQs
When does Bayer report earnings and how could BAYN.DE stock move?
Bayer reports on 04 Mar 2026. BAYN.DE stock may move on guidance for Crop Science and Pharmaceuticals, updates on cash flow and legal provisions. Expect higher intraday volatility and volume on the release.
What is Meyka AI’s short-term forecast for BAYN.DE stock?
Meyka AI’s forecast model projects a 12-month target of €49.38 for BAYN.DE stock, implying about +17.98% upside vs the current €41.85. Forecasts are model-based projections and not guarantees.
What are the top risks to BAYN.DE stock after earnings?
Top risks are weak guidance in Crop Science, unexpected legal charges, and continued leverage pressure. Poor cash flow or lower-than-expected Pharma growth would likely weigh on BAYN.DE stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.